Menu Search
Equities

Genky DrugStores Co Ltd

9267:TYO

Genky DrugStores Co Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (JPY)3,080.00
  • Today's Change45.00 / 1.48%
  • Shares traded23.90k
  • 1 Year change+21.26%
  • Beta0.6390
Data delayed at least 20 minutes, as of Nov 15 2024 02:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in JPY

The 2 analysts offering 12 month price targets for Genky DrugStores Co Ltd have a median target of 4,300.00, with a high estimate of 4,300.00 and a low estimate of 4,300.00. The median estimate represents a 41.68% increase from the last price of 3,035.00.
High41.7%4,300.00
Med41.7%4,300.00
Low41.7%4,300.00

Dividends in JPY

In 2024, Genky DrugStores Co Ltd reported a dividend of 12.75 JPY, which represents a 2.00% increase over last year. The 2 analysts covering the company expect dividends of 13.00 JPY for the upcoming fiscal year, an increase of 1.96%.
Div growth (TTM)2.00%
More ▼

Earnings history & estimates in JPY

Genky DrugStores Co Ltd reported annual 2024 earnings of 208.21 per share on Jul 29, 2024.
Average growth rate+26.83%
More ▼

Revenue history & estimates in JPY

Genky DrugStores Co., Ltd. had 1st quarter 2025 revenues of 50.05m. This missed the 51.41m estimate of the one analyst following the company. This was 6.78% above the prior year's 1st quarter results.
Average growth rate+1.76%
Genky DrugStores Co., Ltd. had revenues for the full year 2024 of 184.86m. This was 9.35% above the prior year's results.
Average growth rate+10.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.